Preparation, characterization and anti-glioma effects of docetaxel-incorporated albumin-lipid nanoparticles

Journal of Biomedical Nanotechnology

Volumn 11, Issue 12, 2015, Pages 2137-2147

  Gao, Huile ^a,b   Cao, Shijie ^b   Yang, Zhi ^b   Zhang, Shuang ^b   Zhang, Qizhi ^b   Jiang, Xinguo ^b  

^a SICHUAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Albumin lipid nanoparticles; Docetaxel; Glioma

Indexed keywords

CELL CULTURE; CELL DEATH; NANOPARTICLES; PARTICLE SIZE;

AQUEOUS SOLUBILITY; DOCETAXEL; ENHANCED PERMEATION AND RETENTIONS; GLIOMA; IN-VIVO IMAGING; LIPID NANOPARTICLES; MEDIAN LETHAL DOSE; MEDIAN SURVIVAL;

TUMORS;

ALBUMIN; DOCETAXEL; LIPID; NANOPARTICLE; PHOSPHATIDYLCHOLINE; ANTINEOPLASTIC AGENT; BOVINE SERUM ALBUMIN; TAXOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DISPERSION; DRUG ANALYSIS; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RETENTION; DRUG SYNTHESIS; EGG YOLK; FEMALE; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LD50; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; ZETA POTENTIAL; ANIMAL; BOVINE; CHEMISTRY; DRUG EFFECTS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CATTLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GLIOMA; HUMANS; LETHAL DOSE 50; LIPIDS; MALE; MICE; NANOPARTICLES; SERUM ALBUMIN, BOVINE; TAXOIDS;

EID: 84953344458     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2015.2076     Document Type: Article

References (33)

1. K. A. Lyseng-Williamson and C. F. Docetaxel, A review of its use in metastatic breast cancer. Drugs 65, 2513 (2005).
2. D. P. Ryan, M. H. Kulke, C. S. Fuchs, M. L. Grossbard, S. R. Grossman, J. A. Morgan, C. C. Earle, R. Shivdasani, H. Kim, R. J. Mayer, and J. W. Clark, A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 94, 97 (2002).
3. S. Cascinu, F. Graziano, S. Barni, R. Labianca, G. Comella, R. Casaretti, L. Frontini, V. Catalano, A. M. Baldelli, and G. Catalano, A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. Br. J. Cancer 84, 470 (2001).
4. K. K. Upadhyay, A. N. Bhatt, E. Castro, A. K. Mishra, K. Chuttani, B. S. Dwarakanath, C. Schatz, J. F. Le Meins, A. Misra, and S. Lecommandoux, In vitro and in vivo evaluation of docetaxel loaded biodegradable polymersomes. Macromol. Biosci. 10, 503 (2010).
5. M. E. Trudeau, Docetaxel: A review of its pharmacology and clinical activity. Can. J. Oncol. 6, 443 (1996).
6. A. M. Yvon, P. Wadsworth, and M. A. Jordan, Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Biol. Cell. 10, 947 (1999).
7. H. Gao, Z. Pang, S. Pan, S. Cao, Z. Yang, C. Chen, and X. Jiang, Anti-glioma effect and safety of docetaxel-loaded nanoemulsion. Arch. Pharm. Res. 35, 333 (2012).
8. H. Gao, J. Qian, S. Cao, Z. Yang, Z. Pang, S. Pan, L. Fan, Z. Xi, X. Jiang, and Q. Zhang, Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials 33, 5115 (2012).
9. M. Zhao, M. Su, X. Lin, Y. Luo, H. He, C. Cai, and X. Tang, Evaluation of docetaxel-loaded intravenous lipid emulsion: Pharmacokinetics, tissue distribution, antitumor activity, safety and toxicity. Pharm. Res. 27, 1687 (2010).
10. H. Gao, J. Qian, Z. Yang, Z. Pang, Z. Xi, S. Cao, Y. Wang, S. Pan, S. Zhang, W. Wang, X. Jiang, and Q. Zhang, Whole-cell SELEX aptamer-functionalised poly(ethyleneglycol)-poly(epsiloncaprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials 33, 6264 (2012).
11. Z. Xu, L. Chen, W. Gu, Y. Gao, L. Lin, Z. Zhang, Y. Xi, and Y. Li, The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 30, 226 (2009).
12. A. Laouini, C. Jaafar-Maalej, I. Limayem-Blouza, S. Sfar, C. Charcosset, and H. Fessi, Preparation, characterization and applications of liposomes: State of the art. J. Colloid Sci. Biotech. 1, 147 (2012).
13. S. Mazzaferro, K. Bouchemal, A. Maksimenko, R. Skanji, P. Opolon and G. Ponchel, Reduced intestinal toxicity of docetaxel loaded into mucoadhesive nanoparticles, in mouse xenograft model. J. Colloid. Sci. Biotech. 1, 210 (2012).
14. I. C. Henderson and V. Bhatia, Nab-paclitaxel for breast cancer: A new formulation with an improved safety profile and greater efficacy. Expert. Rev. Anticancer Ther 7, 919 (2007).
15. Q. Fu, J. Sun, W. Zhang, X. Sui, Z. Yan and Z. He, Nanoparticle albumin-bound (NAB) technology is a promising method for anticancer drug delivery. Recent Pat. Anticancer Drug. Discov. 4, 262 (2009).
16. B. Damascelli, G. Cantu, F. Mattavelli, P. Tamplenizza, P. Bidoli, E. Leo, F. Dosio, A. M. Cerrotta, G. Di Tolla, L. F. Frigerio, F. Garbagnati, R. Lanocita, A. Marchiano, G. Patelli, C. Spreafico, V. Ticha, V. Vespro, and F. Zunino, Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer 92, 2592 (2001).
17. M. Bredel, Anticancer drug resistance in primary human brain tumors. Brain Res. Brain Res. Rev. 35, 161 (2001).
18. W. M. Pardridge, Drug targeting to the brain. Pharm. Res. 24, 1733 (2007).
19. S. Agarwal, R. Sane, R. Oberoi, J. R. Ohlfest, and W. F. Elmquist, Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev. Mol. Med. 13, 17 (2011).
20. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control Release 65, 271 (2000).
21. H. Gao, Y. Wang, C. Chen, J. Chen, Y. We, S. Cao, and X. Jiang, Incorporation of lapatinib into core-shell nanoparticles improves both the solubility and anti-glioma effects of the drug. Int. J. Pharm. 461, 478 (2014).
22. C. Zhan and W. Lu, The blood-brain/tumor barriers: Challenges and chances for malignant gliomas targeted drug delivery. Curr. Pharm. Biotechnol. 13, 2380 (2012).
23. H. Gao, Z. Pang, and X. Jiang, Targeted delivery of nanotherapeutics for major disorders of the central nervous system. Pharm. Res. 30, 2485 (2013).
24. S. Jones-Bolin, H. Zhao, K. Hunter, A. Klein-Szanto, and B. Ruggeri, The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Mol. Cancer Ther. 5, 1744 (2006).
25. H. Gao, Z. Yang, S. Zhang, S. Cao, S. Shen, Z. Pang, and X. Jiang, Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci. Rep. 3, 2534 (2013).
26. H. Gao, Z. Yang, S. Cao, Z. Xi, S. Zhang, Z. Pang, and X. Jiang, Behavior and anti-glioma effect of lapatinib-incorporated lipoprotein-like nanoparticles. Nanotechnology 23, 435101 (2012).
27. H. Gao, Z. Yang, S. Zhang, S. Cao, Z. Pang, X. Yang, and X. Jiang, Glioma-homing peptide with a cell-penetrating effect for targeting delivery with enhanced glioma localization, penetration and suppression of glioma growth. J. Control Release 172, 921 (2013).
28. T. Delmas, A. Fraichard, P. Bayle, I. Texier, M. Bardet, J. Baudry, J. E. R. O. Bibette, and A. Couffin, Encapsulation and release behavior from lipid nanoparticles: Model study with nile red fluorophore. J. Colloid Sci. Biotechnol. 1, 16 (2012).
29. K. Hu, J. Li, Y. Shen, W. Lu, X. Gao, Q. Zhang, and X. Jiang, Lactoferrin-conjugated PEG-PLA nanoparticles with improved braindelivery: In vitro and in vivo evaluations. J. Control Release 134, 55 (2009).
30. W. Lu, Y. Zhang, Y. Z. Tan, K. L. Hu, X. G. Jiang, and S. K. Fu, Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J. Control Release 107, 428 (2005).
31. X. Gao, W. Tao, W. Lu, Q. Zhang, Y. Zhang, X. Jiang, and S. Fu, Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials 27, 3482 (2006).
32. P. Forsyth, G. Cairncross, D. Stewart, M. Goodyear, N. Wainman, and E. Eisenhauer, Phase II trial of docetaxel in patients with recurrent malignant glioma: A study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 14, 203 (1996).
33. M. Sanson, M. Napolitano, R. Yaya, F. Keime-Guibert, P. Broet, K. Hoang-Xuan, and J. Y. Delattre, Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J. Neurooncol. 50, 245 (2000).